PISCATAWAY, N.J.,
April 24,
2024 /PRNewswire/ -- Recently, GenScript Biotech
Corporation (HK.1548), a world leader in technologies and services
for life science R&D and manufacture, released its 2023
Environmental, Social, and Governance (ESG) report. This report
showcases the company's dedicated efforts in ESG governance,
corporate social responsibility fulfillment, and environmental
conservation practices. It underscores GenScript's unwavering
commitment to advancing green initiatives and seamlessly
integrating sustainable development strategies, reaffirming its
strong belief in sustainability.
GenScript's ESG plan embodies its comprehensive and in-depth
enhancement strategy, focusing on optimizing production processes,
deepening customer R&D support, and advancing lean operations
to enhance overall ESG performance. GenScript believes that ESG
practices complement business growth, driving sustainable business
expansion and positively impacting human society's sustainability.
Through close collaboration with customers and continuous
improvement of ESG standards, GenScript actively contributes to
society.
In strengthening corporate ESG governance, GenScript
demonstrates firm determination and systematic planning. The
company establishes a risk management and ESG committee at the
board level and deploys a cross-departmental ESG management team to
continuously monitor and improve ESG practices. Additionally,
GenScript maintains high ethical standards, providing
anti-corruption training for all employees, strengthening
institutional construction, and implementing rigorous annual audit
plans to ensure strict compliance with business ethics and legal
regulations, thus enhancing risk management and ESG governance.
In terms of fulfilling social responsibilities, GenScript
adheres to sustainability as its core value, striving to provide
safer and more reliable products and services to global customers.
The company actively promotes the development of green and
resilient supply chains with its supplier partners, integrating ESG
indicators into supplier evaluations and cooperation mechanisms to
drive transparency and performance improvement throughout the
supply chain's lifecycle.
Moreover, GenScript prioritizes employee growth and well-being,
fostering an inclusive and diverse corporate culture. Through
comprehensive training systems, diversified career development
channels, and efficient communication mechanisms, the company
promotes symbiotic growth between employees and the organization.
Furthermore, GenScript engages in philanthropic activities, such as
organizing "Rare Disease Awareness Weeks", donating to
earthquake-stricken areas, and hosting nationwide universities
relay charity events, enriching the company's social responsibility
endeavors with tangible actions.
The ESG report further illustrates GenScript's environmental
practices, emphasizing resource management, waste management, and
proactive green actions to combat climate change. By establishing a
scientific and efficient environmental management system,
optimizing resource utilization, and exploring clean energy
transitions, GenScript reduces its environmental footprint. The
company implements energy-saving measures such as continuous
improvement of production and equipment processes and waste heat
recovery, linking environmental performance to management
evaluations from top to bottom.
This year, GenScript has further integrated renewable energy
into its energy portfolio, purchasing green power and investing in
photovoltaic power generation. In April
2024, GenScript joined the Science-Based Targets initiative
(SBTi), committing to scientific carbon goals and planning
comprehensive carbon inventories and product carbon footprint
identification to set scientific carbon targets. These efforts not
only help reduce the company's environmental impact but also assist
its customers in achieving carbon reduction goals, collectively
fostering a favorable pattern of collaborative emission reduction
throughout the industry chain.
Sherry Shao, GenScript's rotating
CEO, said, "2023 was a critical year for GenScript's ESG practices.
We took proactive actions to build a systematic framework for
sustainable development and deeply integrated ESG concepts into the
company's daily operations and long-term planning through the
collaborative efforts of management, employees, and numerous
stakeholders. Here, we sincerely thank all parties for their
continuous support of GenScript's business development. In the
future, we are willing to work hand in hand with all parties to
tirelessly strive for the mission of 'Make People and Nature
Healthier Through Biotechnology'."
In the pursuit of sustainable development and continuous
enhancement of ESG standards, GenScript demonstrates a firm
long-term commitment. In 2023, the company officially joined the
United Nations Global Compact (UNGC) and integrated principles such
as human rights, labor rights, environmental protection, and
anti-corruption into its strategic planning, aiming to leverage the
power of this international platform to deepen innovation and
improvement in the ESG field. With significant improvements in
environmental and sustainable procurement performance, GenScript
was awarded the Bronze Medal by the international renowned provider
of business sustainability ratings EcoVadis in March this year,
ranking among the top 35% of over 130,000 assessed companies.
Moving forward, GenScript will continue to elevate its ESG
standards, seize opportunities, and collaborate with stakeholders
in a more open and transparent manner to collectively advance
sustainable development goals. The "GenScript Biotech 2023 ESG
Report" is available at company's official website:
https://www.genscript.com/gsfiles/esg/2023-ESG-Report.pdf
About GenScript
GenScript Biotech Corporation (HK.1548) is a world leader in
technologies and services for life science R&D and manufacture.
Built upon its solid DNA synthesis technology, the company
comprises four major business units: a life-science services and
products business unit, a biologics contract development and
manufacturing organization (CDMO) business unit, an industrial
synthetic products business unit, and an integrated global cell
therapy company. GenScript accelerates scientific discovery and
therapeutic breakthrough with its customers. Since its founding in
New Jersey, USA in 2002, GenScript
has expanded its operations to serve more than 200,000 customers
across 100 countries with a dedicated team of 6,900 employees. As
of December 31, 2023, 87,700
peer-reviewed journal articles worldwide had cited GenScript 's
services and products. Guided by its mission to make people and
nature healthier through biotechnology, GenScript strives to become
the most trustworthy biotech company in the world.
For more information, please visit GenScript Biotech's official
website
https://www.genscript.com
View original
content:https://www.prnewswire.com/news-releases/genscript-biotech-releases-2023-esg-report-deepening-green-development-practices-constructing-sustainable-future-blueprint-302126232.html
SOURCE GenScript Biotech Corporation